Program
Please Note: All session times for the AACR Virtual Meeting: Tumor Immunology and Immunotherapy are U.S. Eastern Time (ET).
Tuesday, October 5, 2021
Plenary Session 1: Immunometabolism
Plenary Session 2: Advances in Immune Cell Engineering
Plenary Session 3: COVID-19 Immunology in Cancer Patients
Opening Keynote Lectures
wednesday, october 6, 2021
Plenary Session 4: Interrogating the Immune Landscape of Cancer
Plenary Session 5: Therapeutic Targeting of the Tumor Microenvironment
Plenary Session 6: Technology and Systems Biology
Plenary Session 7: Combinatorial Studies to Overcome Resistance to Immunotherapy
Tuesday, October 5, 2021
Plenary Session 1: Immunometabolism
10 A.M.-12 P.m.
Immunometabolism clashes with tumor evolution in the tumor microenvironment
Ping Chih Ho, Ludwig Institute, Lausanne, Switzerland
Tumor microenvironment metabolism in T cell differentiation and dysfunction
Greg M. Delgoffe, University of Pittsburgh, Pittsburgh, Pennsylvania
How metabolism shapes tumor-immune interactions and anti-tumor immunity
Marcia Haigis, Harvard Medical School, Boston, Massachusetts
Oncolytic adenoviruses expressing metabolic targets can improve viro-immunotherapy with bispecific T cell engagers through reducing acidosis in an in vitro model*
Arthur Dyer, University of Oxford, Oxford United Kingdom
The co-expression of VISTA and TIGIT on cytotoxic T cells defines subpopulation with altered immunometabolism*
Cassandra Gilmour, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio
Immuno-reactive cancer organoid models to examine microbiome metabolite effects on immune checkpoint blockade efficacy*
Ethan Shelkey, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina
Break
12-12:15 p.m.
Plenary Session 2: Advances in Immune Cell Engineering
12:15-1:45 p.m.
Engineering enhanced persistence and anti-tumor function for therapeutic human T cells
Caroline Arber, Lausanne University Hospital, Epalinges, Switzerland
CAR NK cells: The future of cancer immunotherapy
Rafet Basar, The University of Texas MD Anderson Cancer Center, Houston, Texas
Chimeric antigen receptor macrophages for the treatment of solid tumors
Saar Gill, University of Pennsylvania, Philadelphia, Pennsylvania
CRISPR-mediated PTPN2 deletion in CAR T cells enhances anti-tumor efficacy*
Xin Du, University of Melbourne, Melbourne, VIC, Australia
Break
1:45-2 p.m.
Plenary Session 3: COVID-19 Immunology in Cancer Patients
2-3:15 p.m.
Impact of immunotherapy on COVID-19 vaccination
Alexander Huang, University of Pennsylvania, Philadelphia, Pennsylvania
Adaptive immune dysregulation in cancer patients with SARS-CoV-2 infection
Santosha Vardhana, Memorial Sloan Kettering Cancer Center, New York, New York
Title to be announced
Elizabeth V. Robilotti, Memorial Sloan Kettering Cancer Center, New York, New York
break
3:15-3:30 p.m.
Keynote lectures
3:30-5 p.m.
Mapping myeloid programs that control tumor immunity
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York
Next generation CAR T cells to overcome resistance
Crystal L. Mackall, Stanford University, Stanford, California
WEDNESDAY, OCTOBER 6, 2021
Plenary Session 4: Interrogating the Immune Landscape of Cancer
10 A.M-12:15 P.m.
The immune contexture and its impact on cancer treatment
Jérôme Galon, INSERM, Paris, France
Cancer evolution: Chromosomal instability and immune evasion
Charles Swanton, Francis Crick Institute, London, England
Title to be announced
Marta Luksza, Icahn School of Medicine at Mount Sinai, New York, New York
Lymph node colonization promotes distant tumor metastasis through the induction of tumor-specific immune tolerance*
Nathan Reticker-Flynn, Stanford University, Menlo Park, California
Reprogramming of naïve B cells in pancreatic cancer subverts humoral immunity*
Yuliya Pylayeva-Gupta, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Revisiting NK cell immunity to prevent breast cancer metastasis*
Ana Luisa Correia, University Hospital Basel, Basel, Switzerland
Quiescent cancer cells form immunotherapy resistant reservoirs by forming an immune suppressive niche*
Judith Agudo, Dana-Farber Cancer Institute, Boston, Massachusetts
Break
12:15-12:30 p.m.
Plenary Session 5: Therapeutic Targeting of the Tumor
12:30-2:15 p.m.
Title to be announced
Johanna A. Joyce, University of Lausanne, Lausanne, Switzerland
Targeting tumor associated macrophages for cancer therapy
Jennifer L. Guerriero, Brigham and Women’s Hospital, Boston, Massachusetts
Immune suppression in cancer and strategies for its reversal
Rosandra Kaplan, National Cancer Institute/ National Institutes of Health, Bethesda, Maryland
Context is everything: Microbiota-specific T follicular helper cells in colorectal cancer*
Abigail Overacre-Delgoffe, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Macrophage promotion of anti-androgen resistance in prostate cancer bone disease*
Binzhi Qian, University of Edinburgh, Edinburgh, United Kingdom
break
2:15-2:30 p.m.
Plenary Session 6: Technology and Systems Biology
2:30-3:45 p.m.
The power of ONE: Immunology in the age of single cell genomics
Ido Amit, Weizmann Institute of Science, Rehovot, Israel
Diet and metabolic therapeutics in cancer
Jason W. Locasale, Duke University, Durham, North Carolina
Mapping the dynamics of immunotherapy to quantify tumor antigenicity
Grégoire Altan-Bonnet, National Cancer Institute, Bethesda, Maryland
Break
3:45-4 P.M.
Plenary Session 7: Combinatorial Studies to Overcome Resistance to Immunotherapy
4-5:30 p.m.
What does not kill it makes it stronger: Acquired resistance to targeted therapy confers cross-resistance to immunotherapy
Anna C. Obenauf, Research Institute of Molecular Pathology, Vienna, Austria
Title to be announced
Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas
Immunotherapy for melanoma: Checkpoint blockade combinations
Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, New York
Inhibition of MEK1/2 overcomes resistance to aPD-1 blockade in pancreatic ductal adenocarcinoma through modulation of NETosis in tumor-associated neutrophils*
Brian Herbst, Johns Hopkins, Baltimore, Maryland
*Short talk from proffered abstract